On this page
Upadacitinib (brand name Rinvoq) is a tablet for ulcerative colitis (UC) and Crohn's disease (CD). Unlike biologic medicines, which are given by drip or injection, it is taken by mouth once a day, and it often starts to work within days.
What is it and how does it work?
Upadacitinib belongs to a group of medicines called JAK inhibitors. Inside immune cells, enzymes called Janus kinases (JAKs) pass on the signals from many of the chemical messengers that drive inflammation. Upadacitinib blocks some of these enzymes, which damps down the inflammation. Because it is a small molecule rather than a protein, it can be taken as a tablet, and the body doesn't make antibodies against it.
Other JAK inhibitors used in IBD are tofacitinib and filgotinib, which are used for UC.
What is it used for?
Moderate to severe UC or CD that hasn't responded to, or can't be treated with, other medicines, which may include steroids, immunosuppressants and biologics.
Because of the safety warnings below, it is used with extra care, or only if there is no suitable alternative, in people aged 65 or over, people who smoke or used to smoke for a long time, and people with a higher risk of heart disease, blood clots or cancer.
Before you start
You will have blood tests, including a blood count, liver tests and cholesterol, and checks for tuberculosis (TB), hepatitis B and C and HIV. Your team will review your vaccinations: the non-live shingles vaccine is often recommended before you start, because shingles is more common on JAK inhibitors. Tell your team if you have had blood clots, heart disease, cancer or diverticulitis.
How is it taken?
One tablet a day, with or without food, swallowed whole.
- Starting dose: 45 mg a day, for 8 weeks in UC or 12 weeks in CD.
- Then: usually 15 mg or 30 mg a day, depending on how you respond and on your risk factors.
Many people notice an improvement in the first week or two. Avoid grapefruit and grapefruit juice, and tell any doctor, dentist or pharmacist that you take upadacitinib, because some medicines, including some antibiotics and antifungals, affect its level in the blood.
Blood tests
You will have blood tests regularly, particularly in the first few months, to check your blood count, liver and, about 12 weeks after starting, your cholesterol. Keeping to these tests is important for your safety.
Side effects
Common:
- Colds, sore throat and chest infections
- Acne
- Raised cholesterol, which can be treated if needed
- Changes in blood counts or liver tests, found on routine blood tests
- Nausea, headache and tiredness
- Shingles (a painful, blistering rash, usually on one side of the body). Contact your GP or team promptly if you get it, as early treatment helps.
Infections. Upadacitinib reduces your ability to fight some infections, and serious infections can occur. Contact your team or GP if you have a fever or feel unwell, and tell them you take upadacitinib.
Important safety warnings
In a large study of a related medicine (tofacitinib) in people with rheumatoid arthritis aged 50 or over with at least one heart risk factor, JAK inhibitors were linked to a higher risk of heart attacks and strokes, blood clots, some cancers and serious infections than anti-TNF medicines. The MHRA has applied these warnings to all JAK inhibitors.
Seek medical help straight away if you have:
- Chest pain or tightness, or sudden breathlessness
- Pain, swelling or redness in one leg, which could be a blood clot
- Sudden weakness or numbness on one side, slurred speech or a drooping face
Your team will use the lowest effective dose, especially if any of these risks apply to you, and will discuss with you whether the benefits outweigh the risks.
Vaccinations
Don't have live vaccines shortly before or while taking upadacitinib. These include yellow fever, oral typhoid and MMR. Non-live vaccines are safe and recommended, including the yearly flu injection, COVID-19, pneumococcal and the non-live shingles vaccine.
Pregnancy and breastfeeding
Upadacitinib must not be taken during pregnancy, as it could harm an unborn baby. If you could become pregnant, use effective contraception while taking it and for 4 weeks after the last dose. If you become pregnant, or want to, talk to your IBD team straight away; they can switch you to a medicine that is suitable in pregnancy. You should not breastfeed while taking it.
See Pregnancy and Inflammatory Bowel Disease.
Surgery, dental work and travel
Tell your surgeon or dentist that you take upadacitinib; you may be asked to pause it around an operation. Tablets are easy to travel with: take enough for the whole trip in your hand luggage. See Travel Insurance with Crohn's or Colitis.
If upadacitinib does not work
Your team may adjust the dose, or switch you to another medicine, such as a biologic (infliximab, adalimumab, vedolizumab, ustekinumab or risankizumab). See Medicines for Crohn's Disease and Ulcerative Colitis.
Never stop upadacitinib without discussing it with your IBD team first.